Physician profile
Birju Bhatt
NPI 1881912236
$2,084.00
in general payments reported to CMS, 2019-2025
10 companies · $637 in 2025
The $637 reported for 2025 was less than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $125 · 2022: $155 · 2023: $499 · 2024: $668 · 2025: $637.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,608 · Education: $196.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,608.15 |
| Education | $195.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $517.45 | 2022-2025 | Skyrizi, Rinvoq |
| Novartis Pharmaceuticals Corporation | $458.90 | 2023-2025 | |
| Amgen INC. | $365.67 | 2024-2025 | Tavneos, Uplizna, Evenity |
| Sanofi-Aventis U.S. LLC | $249.18 | 2021-2024 | |
| Janssen Biotech, INC. | $234.23 | 2023-2025 | Tremfya |
| Ucb, INC. | $91.92 | 2022-2025 | Bimzelx, Cimzia |
| Pfizer INC. | $89.64 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $32.87 | 2025 | Orencia |
| Alexion Pharmaceuticals, INC. | $28.34 | 2023 | Strensiq |
| Mallinckrodt Hospital Products INC. | $15.80 | 2025 | Acthar |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Birju Bhatt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.